HIGHLIGHTS
- who: Ambreen Pandrowala from the (UNIVERSITY) have published the article: Narsoplimab for severe transplant-associated thrombotic microangiopathy, in the Journal: (JOURNAL)
- what: The authors report a pediatric patient who recovered from severe TATMA despite having multiple risk factors, such as very low haptoglobin, proteinuria > 30 mg/dl, and transplant with a haploidentical donor .
SUMMARY
Complement activation caused by endothelial injury during stem_cell transplant occurs due to toxicities of medicines used for conditioning, use of immunosuppressant medications, and infection. The authors describe the use of Narsoplimab in a pediatric patient with severe . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.